Pomhex, a cell-permeable potent enolase inhibitor with anticancer activity, is used in the study of cancer lethality.Pomhex, a racemic mixture, is a potent and selective ENO2 inhibitor.Pomhex is inhibitory to the glycolytic process, and shows anticancer activity at low concentrations in an ENO1-deficient tumor model.Pomhex, a cell-permeable potent enolase inhibitor with anticancer activity, is a potent and selective ENO2 inhibitor.

POMHEX (78 nM, 8h) exhibits minimal impact on ENO1-WT glioma cells but significantly affects cells with ENO1 deletion[1]. POMHEX (0-720 nM) selectively induces energy stress, inhibits proliferation, and triggers apoptosis in ENO1-deleted glioma cells[1].

When administered intravenously or intraperitoneally at a dosage of 10 mg/kg (body weight) per day, POMHEX is well-tolerated without inducing hemolytic anemia. However, intravenous injection of POMHEX at 35 mg/kg causes lethargy and necessitates euthanasia by veterinarians[1].
POMHEX rapidly hydrolyzes to Hemi POMHEX in mouse plasma ex vivo, with a half-life of approximately 30 seconds, and in human blood ex vivo, the half-life is around 9 minutes[1].